{"id":80358,"date":"2025-11-14T08:04:07","date_gmt":"2025-11-14T08:04:07","guid":{"rendered":"https:\/\/www.europesays.com\/se\/80358\/"},"modified":"2025-11-14T08:04:07","modified_gmt":"2025-11-14T08:04:07","slug":"marknadsfor-fetmalakemedel-kan-vara-olagligt","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/80358\/","title":{"rendered":"Marknadsf\u00f6r fetmal\u00e4kemedel \u2013 kan vara olagligt"},"content":{"rendered":"<p>V\u00e5rdf\u00f6retag s\u00e4ljer abonnemang p\u00e5 viktminskningsl\u00e4kemedel samtidigt som man annonserar p\u00e5 sociala medier. Men det \u00e4r \u201dhelt ostridigt att det \u00e4r olagligt att marknadsf\u00f6ra preparaten\u201d, s\u00e4ger Claes Granmar, docent i Europar\u00e4tt vid Stockholms universitet, till Ekot.<\/p>\n<p>Enligt l\u00e4kemedelslagen \u00e4r det inte till\u00e5tet att marknadsf\u00f6ra receptbelagda l\u00e4kemedel med undantag f\u00f6r vissa vacciner. <\/p>\n<p>Abonnemangen kostar mellan 299 och 995 kronor i m\u00e5naden, men sedan tillkommer en l\u00e4kemedelskostnad p\u00e5 upp till 8\u202f000 kronor. <\/p>\n<p>Enligt en l\u00e4kare som Ekot pratat med r\u00f6r det sig om \u201dmedicinsk information\u201d och inte marknadsf\u00f6ring.<\/p>\n<p>Omni \u00e4r politiskt obundna och oberoende. Vi str\u00e4var efter att ge fler perspektiv p\u00e5 nyheterna. Har du fr\u00e5gor eller synpunkter kring v\u00e5r rapportering? <a href=\"https:\/\/omni.se\/marknadsfor-fetmalakemedel-kan-vara-olagligt\/a\/mailto:redaktion@omni.se\" class=\"ArticleActions_contactLink__W2F1M\" rel=\"nofollow noopener\" target=\"_blank\">Kontakta redaktionen<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"V\u00e5rdf\u00f6retag s\u00e4ljer abonnemang p\u00e5 viktminskningsl\u00e4kemedel samtidigt som man annonserar p\u00e5 sociala medier. Men det \u00e4r \u201dhelt ostridigt att&hellip;\n","protected":false},"author":2,"featured_media":80359,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[22,23,26,27,17,21,538,2958,24,25,28,29,15,1206,16,18,34,31,33,32,30,19,20],"class_list":{"0":"post-80358","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-rubriker","8":"tag-breaking-news","9":"tag-breakingnews","10":"tag-featured-news","11":"tag-featurednews","12":"tag-headlines","13":"tag-huvudnyheter","14":"tag-lakemedel-medicinteknik","15":"tag-lakemedelsindustri","16":"tag-latest-news","17":"tag-latestnews","18":"tag-main-news","19":"tag-mainnews","20":"tag-news","21":"tag-novo-nordisk","22":"tag-nyheter","23":"tag-rubriker","24":"tag-se","25":"tag-svenska","26":"tag-sverige","27":"tag-sweden","28":"tag-swedish","29":"tag-top-stories","30":"tag-topstories"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115547017224293448","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/80358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=80358"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/80358\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/80359"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=80358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=80358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=80358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}